Status | In progress |
Technology type | Medicine |
Decision | Selected |
Process | STA Standard |
ID number | 3821 |
Provisional Schedule
Evidence submission received | 22 April 2024 |
Committee meeting: 1 | 11 September 2024 |
Expected publication | 20 November 2024 |
Project Team
Project lead | Vonda Murray |
Email enquiries
- If you have any queries please email tateam3@nice.org.uk
Stakeholders
Companies sponsors | MEDICE Arzneimittel PĆ¼tter GmbH & Co |
Akebia Therapeutics Inc | |
Others | Department of Health and Social Care |
Health Technology Wales (HTW) | |
NHS England | |
Patient carer groups | Kidney Care UK |
Kidney Patient Involvement Network | |
Kidney Research UK | |
National Kidney Federation | |
Polycystic Kidney Disease Charity | |
South Asian Health Foundation | |
Specialised Healthcare Alliance | |
Professional groups | Anaemia Nurse Specialist Association |
Association of Nephrology Nurses | |
Association of Renal Technologists | |
British Association of Urological Nurses | |
British Association of Urological Surgeons | |
British Committee for Standards in Haematology | |
British Geriatrics Society | |
British Society for Genetic Medicine | |
British Society for Haematology | |
Royal College of General Practitioners | |
Royal College of Nursing | |
Royal College of Radiologists | |
Royal College of Pathologists | |
Royal College of Physicians | |
Royal Pharmaceutical Society | |
Royal Society of Medicine | |
Society for DGH Nephrologists | |
UK Clinical Pharmacy Association | |
UK Forum on Haemoglobin Disorders | |
UK Kidney Association | |
UK National Screening Committee | |
UK Renal Pharmacy Group | |
United Kingdom Primary Immunodeficiency Network | |
Urology Foundation | |
Associated guideline groups | NICE - National Guideline Centre |
NICE - National Guideline Alliance | |
National Institute for Health and Care Excellence | |
Associated public health groups | Public Health Wales |
UK Health Security Agency | |
Comparator companies | Amgen UK (darbepoetin alfa) |
Janssen-Cilag (epoetin alfa) | |
Pfizer (epoetin zeta) | |
Roche Products UK (epoetin beta, methoxy polyethylene glycol-epoetin beta) | |
Evidence review group | Peninsula Technology Assessment Group (PenTAG) |
National Institute for Health Research Health Technology Assessment Programme (NETSCC) | |
General commentators | All Wales Therapeutic and Toxicology Centre |
Allied Health Professionals Federation | |
Association of Renal Industries | |
Board of Community Health Councils in Wales | |
British National Formulary | |
Care Quality Commission | |
Department of Health, Social Services and Public Safety for Northern Ireland | |
Healthcare Improvement Scotland | |
Medicines and Healthcare products Regulatory Agency | |
National Association of Primary Care | |
National Pharmacy Association | |
NHS Alliance | |
NHS Confederation | |
Scottish Medicines Consortium | |
Welsh Government | |
Welsh Health Specialised Services Committee | |
Relevant research groups | Cochrane Kidney and Transplant Group |
Cochrane UK | |
Genomics England | |
MRC Clinical Trials Unit | |
National Institute for Health Research |
Timeline
Key events during the development of the guidance:
Date | Update |
---|---|
12 February 2024 | Invitation to participate |
15 December 2023 - 12 January 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 2 |
11 December 2023 | Draft scope documents |
13 September 2023 | Please note that following on from information received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during mid-March 2024 when we will write to you about how you can get involved. |
25 July 2023 | Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course. In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes. |
16 May 2023 | Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Vadadustat for treating anaemia in people with chronic kidney disease [ID3821] have been revised. It is anticipated that the appraisal will begin in early-August 2023 when we will write to you about how you can get involved. |
13 September 2022 | As you will be aware, the Department for Health & Social Care has asked NICE to conduct an appraisal of Vadadustat within its marketing authorisation for treating anaemia in people with chronic kidney disease. Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early-August 2023. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
28 March 2022 - 27 April 2022 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
18 February 2021 | In progress. DHSC referral received |
For further information on our processes and methods, please see our CHTE processes and methods manual